Skip to main content
Log in

Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells

  • ORIGINAL ARTICLE
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

 Although schedule-dependent cytotoxicity of etoposide has been reported, its mechanisms have not been elucidated fully. In this study, we attempted to clarify what concentration, time or exposure dose (ED, concentration of drug×time) of etoposide result in the antitumor effect on human ovarian cancer cells from the standpoint of cell cycle perturbation. The different ED were produced by different drug treatment schedules: 10 μg/ml×4 h (ED 40), 1.66 μg/ml×24 h (ED 40), 5 μg/ml×4 h (ED 20), 0.83 μg/ml×24 h (ED 20), 10 μg/ml×0.8 h (ED 8), 5 μg/ml×1.6 h (ED 8), 2 μg/ml×4 h (ED 8), 0.33 μg/ml×24 h (ED 8). Cell cycle perturbation on day 5 and the suppression of cell growth were dependent on the drug concentration at the lowest exposure dose (ED 8), but were dependent on ED at the higher EDs (20 or 40). The percentage of cells in the G2/M fraction significantly decreased from day 5 to day 7 in BG-1 cells treated at ED 20 or treated with higher concentrations (10 and 5 μg/ml) at ED 8, but not in those treated at ED 40 or treated with lower concentrations (2 and 0.33 μg/ml) at ED 8. Therefore, the cytotoxic mechanism of etoposide may not be explained by simple schedule dependency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 1 February 1995/Accepted: 9 October 1995

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohishi, Y., Fujiwara, K. & Kohno, I. Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells. Cancer Chemother Pharmacol 38, 141–146 (1996). https://doi.org/10.1007/s002800050462

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800050462

Navigation